Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » GenMark Diagnostics Q1 Revenues Grow 80 Percent

GenMark Diagnostics Q1 Revenues Grow 80 Percent

May 04, 2020
|
staff reporter

NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Monday that its first quarter revenues rose 80 percent, driven in part by continued sales growth of its ePlex molecular diagnostics analyzer and by its SARS-CoV-2 test.

The company also announced interim CEO Scott Mendel had been appointed President and CEO.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Germany to Increase Viral Sequencing

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

Getting Used to It

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

Green Access at Science

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

Science Papers Examine Chronic Kidney Disease GWAS, Pneumonia Microbiome

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

What's Popular?

In Business News

  1. JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

  2. Ancestry to Discontinue NGS-Based AncestryHealth Service

  3. Pacific Biosciences CEO Discusses Q4 Results, New Sequencing Platforms at JP Morgan

  4. JP Morgan Healthcare Conference 2021, Day 2: Roche, Seer, 10x, Guardant, Hologic, Thermo Fisher

  5. Bionano Genomics Stock Soars on User Presentations, Public Stock Offering, Renewed Nasdaq Compliance

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.